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Abstract
Seven percent of renal cell carcinoma (RCC) cases are diagnosed as “unclassified” RCC by morphology. Genetic profiling
of RCCs helps define renal tumor subtypes, especially in cases where morphologic diagnosis is inconclusive. This report
describes a patient with synchronous clear cell RCC (ccRCC) and a tubulocystic renal carcinoma (TCRC) in the same
kidney, and discusses the pathologic features and genetic profile of both tumors. A 67 year-old male underwent CT
scans for an unrelated medical event. Two incidental renal lesions were found and ultimately removed by radical
nephrectomy. The smaller lesion had multiple small cystic spaces lined by hobnail cells with high nuclear grade
separated by fibrous stroma. This morphology and the expression of proximal (CD10, AMACR) and distal tubule cell
(CK19) markers by immunohistochemistry supported the diagnosis of TCRC. The larger lesion was a typical ccRCC, with
Fuhrman’s nuclear grade 3 and confined to the kidney. Molecular characterization of both neoplasms using virtual
karyotyping was performed to assess relatedness of these tumors. Low grade areas (Fuhrman grade 2) of the ccRCC
showed loss of 3p and gains in chromosomes 5 and 7, whereas oncocytic areas displayed additional gain of 2p and
loss of 10q; the high grade areas (Fuhrman grade 3) showed several additional imbalances. In contrast, the TCRC
demonstrated a distinct profile with gains of chromosomes 8 and 17 and loss of 9. In conclusion, ccRCC and TCRC
show distinct genomic copy number profiles and chromosomal imbalances in TCRC might be implicated in the
pathogenesis of this tumor. Second, the presence of a ccRCC with varying degrees of differentiation exemplifies the
sequence of chromosomal imbalances acquired during tumor progression.
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Introduction
Kidney cancer is among the ten most common causes of
cancer-related death in adults [1]. Over 64,700 new
cases and over 13,500 deaths are expected to occur in
the US in 2012 [2]. Renal cell carcinoma (RCC) consti-
tutes more than 80% of all primary renal neoplasms,
and clear cell RCC (ccRCC) accounts for most of these
cases (80%). While a specific histological diagnosis is
possible by morphology and immunohistochemistry in
the majority of cases, overlapping morphological fea-
tures are still encountered in about 7% of cases in rou-
tine practice [3], and these cases fall in the category of
“unclassified renal neoplasm.” Recent updates to the his-
topathological diagnosis of kidney neoplasms are
reflected in the latest World Health Organization
(WHO) classification of genitourinary and kidney neo-
plasms [4]. However, ongoing research has led to the
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sidered in this classification. One of these recently
described entities is tubulocystic renal carcinoma
(TCRC) with less than one hundred cases reported [5].
Genetic events play an important role in renal carci-
nogenesis, and most known renal tumor subtypes have
recurrent specific chromosomal imbalances [6]. Thus,
genetic profiling of renal tumors has emerged as a prac-
tical diagnostic tool for the surgical pathologist, espe-
cially in those cases where morphologic diagnosis is not
conclusive [3]. Although the identification of key mole-
cular targets involved in renal carcinogenesis has had
direct impact in patient care, little is known about the
genetic events involved in tumor progression [6].
Herein we describe the clinico-pathological features of
a patient presenting with synchronous ccRCC and a
TCRC and the molecular profiles of these tumors utiliz-
ing virtual karyotyping. Our results contrast the different
profiles of these tumors as well as exemplify the chro-
mosomal imbalances associated with histologic progres-
sion from low to highgrade ccRCC.
Case presentation
A 67-year-old previously healthy male presented with
acute onset of chest pain. His past medical history was
unremarkable except for a history of RCC in his mother.
The patient’s physical exam and cardiac workup were
negative. Two incidental right renal masses were found
on CT scan performed as part of his chest pain evalua-
tion (Figure 1). A 3.5 cm, solid, enhancing mass located
in the anterior aspect of the upper pole; and a 1.2 cm
mass located along the mid lateral aspect of the kidney.
The patient denied flank pain, hematuria, or weight loss.
Additional workup for metastatic disease was negative.
Partial nephrectomy was attempted to remove the
lesions; however, a total nephrectomy was ultimately
necessary. No adjuvant therapy was administered to the
patient. Twenty-four months after the procedure, the
patient remains free of disease.
Gross and microscopic findings
At surgery, a wedge biopsy including the smaller lesion
was initially submitted for frozen section and was inter-
preted as TCRC vs. cystic nephroma, followed by a par-
tial nephrectomy of a larger lesion interpreted as a
ccRCC. The smaller nodule (2 × 1.7 × 1 cm) was a tan-
gray small sphere with a spongy cut surface that was
adjacent to a 0.3 cm hemorrhagic cyst. The larger
tumor was a relatively well encapsulated tan-yellow to
red mass (4.1 × 3.4 × 2.5 cm) macroscopically compati-
ble with ccRCC which showed no association with the
previous smaller lesion (Figure 2A). A radical nephrect-
omy was ultimately performed.
Microscopically, the smaller lesion was composed of
multiple cystic tubules of variable size separated by fibro-
vascular septae (Figure 2B, arrows). The tubules were
lined by flat to polygonal and epithelioid cells displaying
a prominent hobnail pattern. There was nuclear enlarge-
ment, prominent nucleoli, and eosinophilic cytoplasm
(Figure 3A-B), but mitotic figures were not observed.
Some tubules occasionally contained intraluminal clumps
of eosinophilic acellular material. By immunohistochem-
istry, the tubular cells were positive for alpha-methylacyl-
CoA racemase (AMACR), CD10 and cytokeratin 19 (CK
19), which are markers commonly positive in TCRC
tumors (Figure 3C) [7,8], while the stromal cells were
negative for estrogen receptor. In contrast, the larger
tumor was primarily composed of nests of cells with
abundant clear cytoplasm with well-demarcated cellular
borders and hyperchromatic nuclei with inconspicuous
nucleoli (Furhman nuclear grade 2) separated by a well-
formed capillary network. In some areas, the tumor
showed well-demarcated nodules with oncocytic change
together with mild nuclear pleomorphism and slightly
Figure 1 Imaging, Computed tomography (CT) showed the
presence of two incidental well-circumscribed masses with
similar density in the right kidney. The larger lesion was solid
and enhancing and measured 3.5 cm; it was located in the upper
pole and approached but did not extend into the renal sinus (black
arrow). The smaller lesion measured 1.2 cm and was located along
the mid lateral aspect of the kidney (white arrow). The contralateral
kidney was normal.
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of the tumor contained cells with marked pleomorphism,
irregular nuclear contours, and prominent nucleoli
(Furhman nuclear grade 3) (Figure 4C). Sarcomatoid fea-
tures were not present. A final diagnosis of synchronous
TCRC and ccRCC, Fuhrman nuclear grade 3, Stage T1b,
was established.
Virtual karyotyping
DNA was extracted from microdissected tumor tissue
from the clear cell and oncocytic areas with Fuhrman
grade 2, the region of ccRCC with Fuhrman grade 3,
from the TCRC, and from uninvolved kidney tissue. Vir-
tual karyotyping was done using Affymetrix 250 K Nsp
SNP (single nucleotide polymorphism) arrays as
described previously [3]. Results for SNP oligonucleotide
microarray karyotype analysis for each region of the
tumors and normal kidney are shown in Figure 5. All
analyzed areas of the ccRCC showed characteristic loss
of chromosome 3p and gains in chromosomes 5 and 7.
In addition to these findings, the area of oncocytic
change showed a gain of 2p and a loss of 10q. The area
Figure 2 Gross image and full-montage of the ccRCC and TCRC, respectively. A) The larger mass was well encapsulated, tan-yellow to
red and grossly suggestive of ccRCC. This lesion was not associated with the smaller nodule. B) Full-montage of the smaller lesion. The
‘spongy’ nodule encountered in the gross description (arrows) was composed of cystically-dilated irregular tubules of different sizes, separated
by fibrovascular septae (H&E).
Figure 3 Tubulocystic carcinoma component. A) Higher magnification of the image shown on figure 2B (H&E, 4×). B) The cystically-dilated
tubules were lined by flat to polygonal cells (some with a hobnail profile) with enlarged nucleus, prominent nucleolus, and occasional abundant
eosinophilic cytoplasm. The fibrous septae contained scattered fibroblast-like spindle cells interspersed within a collagenous stroma (H&E, 20×).
C) Tubular cells were positive for AMACR (left, top) and CD10 (left, bottom), and CK19 (right) confirming their proximal and distal convoluted
tubule cell origin, respectively (all images, 20×). Estrogen receptor was negative in both epithelial and stromal elements (not shown).
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file consistent with polyploidy (likely trisomic) with the
following additional imbalances: +2,+5,-6,+7,+10,+12,
+15,+16,+17,+18,+19,+20,+21. The TCRC displayed a
profile distinct from that of the ccRCC, with gains of
chromosomes 8 and 17 and loss of chromosome 9. The
non-neoplastic kidney showed no chromosomal gains or
losses. However, uniparental disomy in regions of chro-
mosomes 2 and 6 [UPD2 (q21.3-q22.1), UPD6 (q23.2-
q23.3)] was found in tumoral and non-neoplastic kidney
from the patient (asterisks, Figure 5), indicating a germ-
line abnormality.
Discussion
We report a case of two synchronous non-related
tumors, a TCRC and a ccRCC occurring in the same
kidney with molecular characterization of both
neoplasms.
TCRC was originally described by Masson who named
it “Bellinian epithelioma” or “carcinoma of the collecting
ducts” as he believed it originated from collecting ducts
of Bellini [9]. MacLennan et al. [10] in 1997 hypothe-
sized that this tumor represented the low grade of the
spectrum of collecting duct carcinoma, as it shares simi-
lar characteristics with the latter tumor (i.e., immunopo-
sitivity for 34bE12 and UEA-1). In 2004, Amin et al.
named the tumor “tubulocystic carcinoma” in a series of
29 cases [11].
TCRC is a rare entity that characteristically has a
small size at presentation (mean 2 cm) and rarely pro-
gresses, recurs, or metastasizes [7,8,12,13]. It has been
reported in association with other RCCs, primarily
papillary RCC [5]. Recent immunohistochemical, ultra-
stuctural, and molecular studies (RNA expression levels
and genomic profile analyses) have shown that TCRC is
different from collecting duct carcinoma and may be
related to papillary RCCs [5,7,8,13-15]. Supportive find-
ings include the expression of proximal convoluted
tubule markers (CD10 and AMACR), distal nephron
proteins (parvalbumin, HMWCK and CK19) [5,7], and
the detection of cells reminiscent of proximal tubule
and intercalated cells by electron microscopy [5,13-15].
Further supporting the notion that TCRC is related to
papillary RCC is the report of one group that described
that TCRC has a gene expression profile similar to that
of papillary RCCs using cluster analysis [8]. However,
another study showed a distinct gene expression profile
characterized by expression of cell cycle and biomole-
cule metabolism genes although this group did not com-
pare this profile directly to papillary tumors [5]. Using
fluorescence in situ hybridization (FISH) and array-
based comparative genomic hybridization (aCGH), Zhou
Figure 4 Clear cell RCC component. A) The largest lesion described in the gross description was composed of cells with abundant clear
cytoplasm and well-demarcated cellular borders. Marked oncocytic changes with a nodular configuration were present in some areas (H&E, 2×).
B) The rectangle in A at higher magnification shows the transition between the clear (top) and oncocytic cells (bottom). Nuclear features in the
clear cell areas were consistent with Furhman nuclear grade 2, whereas the oncocytic nodule’s cells showed increased pleomorphism and
slightly enlarged nucleoli (H&E, 10×). C) A separate area of the tumor showed clusters of tumor cells with marked nuclear pleomorphism,
irregular nuclear contours, and prominent nucleoli, consistent with Furhman nuclear grade 3 (H&E, 40×).
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mosome 17, as is seen with papillary RCCs and thus
have proposed that these two entities are closely related.
Our case showed classic features of TCRC, such as
positive immunohistochemistry for CD10, AMACR and
CK19, as well as gains of chromosome 17 in the virtual
karyotyping analysis. In addition, the TCRC also showed
gains in chromosome 8 and loss of chromosome 9
( F i g u r e5 ) .T h ec h r o m o s o m a li m b a l a n c ep a t t e r n
observed in our TCRC case is distinct from that found
in papillary RCC which commonly shows gains of 7 and
1 7a n dr a r e l ys h o w sg a i n so f8o rl o s so f9[ 6 ] .I m p o r -
tantly, loss of chromosome 9 and gain of 17 seem to be
recurrent chromosomal imbalances in TCRC tumors
(Monzon and Amin, unpublished observations). If this is
confirmed in a large case series, it could help establish
Figure 5 Genomic profile of tumor components. The uppermost plot for each sample represents the estimated copy number as a log 2 ratio
averaged over 30 SNPs; middle bar represents a color-coded Hidden Markov Model (HMM) for copy number (yellow = copy number 2, pink =
copy number 3, aqua = copy number 1), and bottom bar is a color-coded HMM for LOH (yellow = no LOH, blue = LOH). Genomic analysis
revealed loss of chromosome 3p and gains in chromosomes 5 and 7 in all ccRCC components, a gain of 2p and loss of 10q in the oncocytic
component, and a profile consistent with polyploidy (likely trisomic) with additional gains and losses in the high-grade component. The
tubulocystic component showed a profile distinct from that of ccRCC. Germline uniparental disomy (UPD) of chromosomes 2 and 6 [UPD2
(q21.3-q22.1), UPD6 (q23.2-q23.3)] (asterisks) was found in all (tumor and normal) specimens from the patient.
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RCC. It is important to notet h a tt h ec y s t i ca n ds o m e -
what paucicellular nature of the tumor may be an
important consideration when performing molecular
analyses of this tumor subtype, since stromal cells may
play a role as contaminants. Also, the role of stromal
cells in the pathogenesis of TCRC remains uncertain,
since metastatic cases not only show the cystic glandular
configurations but also the intervening stroma [5].
The differential diagnosis of TCRC includes mixed
epithelial and stromal tumor and cystic nephroma [16].
The former, another variant of RCC, is easily ruled out
as typically displays an ovarian-like stroma that is
usually estrogen receptor positive and occurs predomi-
nantly in female patients [17,18]. The so-called cystic
nephroma has become basically a non-existent entity
[17,19]. In the WHO classification of renal tumors [4]
there is an illustration of a cystic nephroma which looks
identical to the TCRC. We suspect that the “cystic
nephroma” is actually the tumor now known as TCRC.
There are sporadic reports about the coexistence of
TCRC with other renal tumors of different subtypes.
Yang et al. reported 5 cases of TCRC associated with
either papillary RCC or papillary adenomas [8]. Gonul
et al. reported a case of synchronous ccRCC, micropa-
pillary urothelial carcinoma and TCRC in a 57-year-old
male with hematuria [20]. Brennan et al. presented a
case of a 72-year-old male with end stage renal disease
who developed a TCRC, a type 2 papillary RCC, a clear
cell papillary and cystic RCC as well as renal oncocyto-
sis, hybrid tumors and chromophobe RCC [21]. More
recently, Deshmukh et al. reported a synchronous
TCRC and papillary RCC in a young female with meta-
static papillary RCC in para-aortic lymph nodes [22].
Thus, although TCRC has been reported in association
with multiple other renal cell tumor subtypes, it appears
that there is a slight predominance for synchronous
TCRC and papillary tumors. An interesting question
raised by the coexistence of TCRC with other renal
tumors is whether there are common predisposing fac-
tors for these histologically different tumors.
The ccRCC in this case showed a spectrum of mor-
phologic variations ranging from low grade to high
grade and a distinct nodule with oncocytic changes
which allowed us to inquire about molecular differences
within morphologic progression in a single tumor. We
analyzed the areas in the ccRCC showing different grade
and morphology using virtual karyotyping and demon-
strated that a higher Fuhrman grade correlated with an
increase in chromosomal imbalances (Figure 5). In a
similar fashion, studies on chromophobe RCCs have
shown that multiple chromosomal gains are associated
with sarcomatoid transformation [23]. More recently,
Patani et al. using high-resolution aCGH and FISH have
also demonstrated that morphologically distinct regions
from a case of triple-negative breast carcinoma (apoc-
rine vs. non-apocrine areas) correlate with different
genetic aberrations [24].
In addition to the somatically acquired genetic
changes in the tumors, the patient’st u m o rh a dr e g i o n s
of inherited uniparental disomy (UPD, i.e. two chromo-
somal regions inherited from one parent only) in chro-
mosomes 2 and 6 (Figure 5, asterisks). The presence of
these genetic lesions in the normal kidney tissue sug-
gests a possible inherited origin. Although uniparental
disomy has been implicated as a risk factor for colon
and other cancers, its role in the predisposition of renal
tumors is currently unknown [25].
In conclusion, this case allowed us to explore two uses
of whole genome analysis with virtual karyotyping. The
first was to confirm that ccRCC and TCRC have distinct
genomic copy number profiles and that TCRC appears
to have recurrent gains in chromosome 17 which might
be implicated in the pathogenesis of this tumor. Second,
the presence of a ccRCC with varying degrees of differ-
entiation allowed us to evaluate the sequence of chro-
mosomal imbalances acquired during tumor
progression. These findings s u p p o r tt h ec o n c e p tt h a t
chromosomal imbalances are associated with tumor pro-
gression [26], and possibly explain why Fuhrman grad-
ing is a strong prognostic factor in ccRCC [27] even
when high grade cells are present in a minority of the
specimen [28].
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